Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis-Reference-Cited by-同舟云学术

Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis

Published:2021-12-02 Issue: Volume: Page:
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Hiraoka Atsushi¹^ORCID,Kumada Takashi²^ORCID,Tada Toshifumi³^ORCID,Hirooka Masashi⁴,Kariyama Kazuya⁵,Tani Joji⁶,Atsukawa Masanori⁷,Takaguchi Koichi⁸,Itobayashi Ei⁹,Fukunishi Shinya¹⁰,Tsuji Kunihiko¹¹,Ishikawa Toru¹²,Tajiri Kazuto¹³^ORCID,Ochi Hironori¹⁴,Yasuda Satoshi¹⁵,Toyoda Hidenori¹⁵^ORCID,Ogawa Chikara¹⁶,Nishimura Takashi¹⁷,Hatanaka Takeshi¹⁸,Kakizaki Satoru¹⁹^ORCID,Shimada Noritomo²⁰,Kawata Kazuhito²¹^ORCID,Naganuma Atsushi²²,Tanaka Takaaki¹,Ohama Hideko¹⁰,Nouso Kazuhiro⁵^ORCID,Morishita Asahiro⁶^ORCID,Tsutsui Akemi⁸,Nagano Takuya⁸,Itokawa Norio⁷,Okubo Tomomi⁷,Arai Taeang⁷,Imai Michitaka¹²,Koizumi Yohei⁴,Nakamura Shinichiro³,Joko Kouji¹⁴^ORCID,Iijima Hiroko¹⁷,Hiasa Yoichi⁴^ORCID,Kudo Masatoshi²³, ,

Affiliation:

1. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

2. Department of Nursing Gifu Kyoritsu University Ogaki Japan

3. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan

4. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

5. Department of Gastroenterology Okayama City Hospital Okayama Japan

6. Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan

7. Division of Gastroenterology and Hepatology Department of Internal Medicine Nippon Medical School Tokyo Japan

8. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

9. Department of Gastroenterology Asahi General Hospital Asahi Japan

10. Department of Gastroenterology Osaka Medical College Osaka Japan

11. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

12. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

13. Department of Gastroenterology Toyama University Hospital Toyama Japan

14. Hepato‐Biliary Center Japanese Red Cross Matsuyama Hospital Matsuyama Japan

15. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan

16. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan

17. Department of Internal Medicine Division of Gastroenterology and Hepatology Hyogo College of Medicine Nishinomiya Japan

18. Department of Gastroenterology Saiseikai Maebashi Hospital Gunma Japan

19. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan

20. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

21. Department of Hepatology Hamamatsu University School of Medicine Hamamatsu Japan

22. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan

23. Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13734

Reference45 articles.

1. Estimating the world cancer burden: Globocan 2000

2. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

3. Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update

4. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

5. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update;Kudo M;Liver Cancer,2021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08

2. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status;World Journal of Hepatology;2024-03-27

3. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab;Liver International;2024-03-15

4. Impact of hepatectomy and postoperative adjuvant transarterial chemoembolization on serum tumor markers and prognosis in intermediate-stage hepatocellular carcinoma;World Journal of Gastrointestinal Surgery;2023-12-27

5. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey;Medicine;2023-11-10